Kiora Pharmaceuticals, Inc. (KPRX) Financial Ratios
13 years of historical data (2012–2024) · Healthcare · Biotechnology
EV/EBITDA
1.03
↓-53% vs avg
5yr avg: 2.18
30Y Low2.2·High2.2
P/FCF
0.98
↓-38% vs avg
5yr avg: 1.59
30Y Low1.6·High1.6
P/B Ratio
↓
0.39
↓-94% vs avg
5yr avg: 6.57
30Y Low0.4·High43.3
ROE
↑
22.6%
↓+127% vs avg
5yr avg: -84.4%
30Y Low-464%·High23%
Debt/EBITDA
0.01
+0% vs avg
5yr avg: 0.01
30Y Low0.0·High0.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KPRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Kiora Pharmaceuticals, Inc. trades at 2.8x earnings, 26% below its 5-year average of 3.8x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 87%. On a free-cash-flow basis, the stock trades at 1.0x P/FCF, 38% below the 5-year average of 1.6x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $8M | $14M | $3M | $23M | $131M | $204M | $287M | $149M | $137M | $130M | $152M |
| Enterprise Value | $5M | $10M | $180840 | $17M | $123M | $203M | $283M | $141M | $130M | $126M | $144M |
| P/E Ratio → | 2.82 | 3.79 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.53 | 0.85 | — | — | — | 16893.94 | 106.80 | 89.88 | 336.97 | 193.63 | — |
| P/B Ratio | 0.39 | 0.53 | 0.41 | 1.98 | 8.99 | 20.94 | 43.32 | 16.62 | — | — | 24.97 |
| P/FCF | 0.98 | 1.59 | — | — | — | — | — | — | — | — | — |
| P/OCF | 0.98 | 1.59 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KPRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Kiora Pharmaceuticals, Inc.'s enterprise value stands at 1.0x EBITDA, 53% below its 5-year average of 2.2x. The Healthcare sector median is 14.4x, placing the stock at a 93% discount on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.62 | — | — | — | 16843.24 | 105.42 | 85.04 | 317.85 | 188.25 | — |
| EV / EBITDA | 1.03 | 2.18 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 1.04 | 1.74 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 1.15 | — | — | — | — | — | — | — | — | — |
KPRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Kiora Pharmaceuticals, Inc. earns an operating margin of 28.2%. ROE of 22.6% indicates solid capital efficiency. ROIC of 26.2% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | — | — | -27038.7% | 99.8% | -387.5% | -2434.9% | -1158.5% | — |
| Operating Margin | 28.2% | 28.2% | — | — | — | -56960.5% | -260.6% | -656.3% | -3572.7% | -1994.3% | — |
| Net Profit Margin | 22.5% | 22.5% | — | — | — | -56901.7% | -264.2% | -654.2% | -3243.5% | -1993.8% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.6% | 22.6% | -142.9% | -104.5% | -113.3% | -83.9% | -91.2% | -308.5% | — | -463.5% | -137.9% |
| ROA | 14.3% | 14.3% | -77.3% | -70.0% | -77.7% | -54.0% | -58.2% | -75.6% | -110.0% | -138.7% | -153.8% |
| ROIC | 26.2% | 26.2% | -202.8% | -147.9% | -133.0% | -85.5% | -271.6% | -868.3% | — | — | — |
| ROCE | 21.2% | 21.2% | -91.6% | -72.6% | -89.4% | -62.4% | -73.3% | -219.3% | -1537.1% | -313.7% | -540.9% |
KPRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Kiora Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 0.0x, which is very conservative (100% below the sector average of 3.3x). The company holds a net cash position — cash of $4M exceeds total debt of $57170, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 210.3x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.06 | 0.01 | 0.00 | — | — | — |
| Debt / EBITDA | 0.01 | 0.01 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.14 | -0.38 | -0.51 | -0.52 | -0.06 | -0.56 | -0.90 | — | — | -1.38 |
| Net Debt / EBITDA | -0.82 | -0.82 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.44 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 210.31 | 210.31 | -1130.69 | -1431.51 | -2077.91 | -1640.91 | -21541.46 | -10427.60 | -11982.91 | -48533.99 | -3.45 |
Net cash position: cash ($4M) exceeds total debt ($57170)
KPRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Kiora Pharmaceuticals, Inc.'s current ratio of 4.94x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.35x to 4.94x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.94 | 4.94 | 2.90 | 2.35 | 5.59 | 0.87 | 3.06 | 2.19 | 0.57 | 0.57 | 2.76 |
| Quick Ratio | 4.94 | 4.94 | 2.90 | 2.35 | 5.59 | 0.87 | 3.06 | 2.19 | 0.57 | 0.57 | 2.76 |
| Cash Ratio | 4.46 | 4.46 | 1.50 | 1.82 | 4.88 | 0.60 | 2.67 | 2.07 | 0.53 | 0.50 | 2.45 |
| Asset Turnover | — | 0.44 | — | — | — | 0.00 | 0.27 | 0.12 | 0.03 | 0.07 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 13.71 | — | — | — | 2753.62 | 0.66 | 4.07 | 21.21 | 29.36 | — |
KPRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Kiora Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 35.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 35.5% | 26.4% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 100.0% | 62.8% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $4M | $538007 | $732303 | $241099 | $114787 | $79525 | $59139 | $23766 | $14723 | $10273 |
Peer Comparison
Compare KPRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KPRXYou | $8M | 2.8 | 1.0 | 1.0 | 100.0% | 28.2% | 22.6% | 26.2% | 0.0 |
 OCUL | $2B | -6.8 | — | — | 87.3% | -521.0% | -54.9% | — | — |
 LENZ | $278M | -3.4 | — | — | 97.8% | -477.5% | -33.6% | -30.7% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 ALDX | $104M | -1.8 | — | — | — | — | -58.5% | -369.4% | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 REPL | $266M | -1.1 | — | — | — | — | -62.6% | -51.9% | — |
 ADVM | $96M | -0.7 | — | — | 100.0% | -13915.9% | -189.8% | -124.2% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See KPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KPRX vs OCUL
Side-by-side business, growth, and profitability comparison vs Ocular Therapeutix, Inc..
Start ComparisonKPRX — Frequently Asked Questions
Quick answers to the most common questions about buying KPRX stock.
What is Kiora Pharmaceuticals, Inc.'s P/E ratio?
Kiora Pharmaceuticals, Inc.'s current P/E ratio is 2.8x. The historical average is 3.8x.
What is Kiora Pharmaceuticals, Inc.'s EV/EBITDA?
Kiora Pharmaceuticals, Inc.'s current EV/EBITDA is 1.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 2.2x.
What is Kiora Pharmaceuticals, Inc.'s ROE?
Kiora Pharmaceuticals, Inc.'s return on equity (ROE) is 22.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -158.1%.
Is KPRX stock overvalued?
Based on historical data, Kiora Pharmaceuticals, Inc. is trading at a P/E of 2.8x. Compare with industry peers and growth rates for a complete picture.
What are Kiora Pharmaceuticals, Inc.'s profit margins?
Kiora Pharmaceuticals, Inc. has 100.0% gross margin and 28.2% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Kiora Pharmaceuticals, Inc. have?
Kiora Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.